Wednesday, September 17, 2025 9/17/2025

Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosis

Award Number: R56AI188482
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/10/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosis - Immune checkpoints play a key role in regulating hemostasis and maintaining self-tolerance, including in the human autoimmune disease of the central nervous system: multiple sclerosis (MS). We previously employed metabolic glycoengineering and biorthogonal click chemistry to bioengineer immune checkpoint functionalized mouse glial cells. We demonstrated that these immune-checkpoint engineered cells are highly effective in preventing and treating EAE in mice. Based on this exciting preliminary data, we aim to further develop this technology to improve MS treatment. Our overarching hypothesis immune checkpoint engineered oligodendrocytes (OLG) can engage autoreactive immune cells and lead to T cell exhaustion and immune tolerance. We further theorize that we can identify a highly effective combination of immune checkpoints that can provide additive or synergistic effects that regulates CNS autoimmunity. To demonstrate the feasibility of this approach, we developed two specific aims. The first aim will formulate checkpoint engineered OLGs using stem cells and iPSCs. This aim will demonstrate the feasibility of generating autologous oligodendrocytes for checkpoint engineering. Second aim will examine engineered OLGs using MOG and PLP MS models. Our application has high potential impact on the treatment of MS. Our approach of using biomedical engineering and glycochemistry to engineer cell-based treatment is highly innovative and novel. Our work can reveal new mechanistic insights in MS and potential new treatments for MS. In the long term, our work can lead to a new class of therapeutics for MS treatment. Our proposed treatment is highly translatable. Our work can also bring new interest in the application of biomedical engineering approaches to MS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $300,000 )
2025	2025	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Allergy and Infectious Diseases Research	000	1	9/9/2025	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $300,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosis

Award Number: R56AI188482

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/10/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer